Private investment in biotechnology companies continues to churn out startups and support the next stage of drug development for established early-stage firms, despite the rollercoaster rise and fall of public biotech company valuations, with venture capital firms continuing to raise money for new funds and invest the proceeds in new opportunities.
FINANCE ROUNDUP: A New VC Fund, A $60m Collaboration Boost, And 14 Funding Rounds
Private investment in biotechnology companies continues to churn out startups and support the next stage of drug development for established early-stage firms, despite the rollercoaster rise and fall of public biotech company valuations, with venture capital firms continuing to raise money for new funds and invest the proceeds in new opportunities.
More from Alimentary/Metabolic
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
More from Therapy Areas
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.